Matinas BioPharma Holdings (MTNB) Net Margin (2015 - 2023)
Matinas BioPharma Holdings (MTNB) posted quarterly Net Margin of 998.47% for Q2 2023, down 44132.0% year-over-year from N/an in Q2 2022, and up 43.8% quarter-over-quarter from 1776.8% in Q1 2023.
Matinas BioPharma Holdings (MTNB) Net Margin (2015 - 2023) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Net Margin for 8 consecutive years, with 998.47% the latest figure, recorded in Q2 2023.
- In Q2 2023, Net Margin fell 44132.0% year-over-year to 998.47%; the TTM figure through Dec 2023 stood at 2456.57% (down 179808.0% YoY), while the FY2023 annual figure was 2093.25%, down 143462.0% from the prior year.
- Net Margin grew to 998.47% in Q2 2023 per MTNB's latest filing, from 1776.8% in the prior quarter.
- Across five years, Net Margin topped out at 2011779.58% in Q4 2021 and bottomed at 15501.82% in Q1 2021.
- Historically, Net Margin has averaged 199258.79% across 5 years, with a median of 777.82% in 2023.
- Annual changes were most pronounced in 2021 — Net Margin jumped 200134091 bps — and 2022, when it tumbled 201212149 bps.
- Matinas BioPharma Holdings' Net Margin stood at 4016.46% in 2019, then surged by 360 bps to 10438.67% in 2020, then jumped by 19172 bps to 2011779.58% in 2021, then sank by 100 bps to 341.91% in 2022, then plunged by 192 bps to 998.47% in 2023.
- Business Quant data shows MTNB's Net Margin at 998.47% in Q2 2023, 1776.8% in Q1 2023, and 341.91% in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -998.47% |
| Mar 31, 2023 | -1,776.80% |
| Dec 31, 2022 | -341.91% |
| Sep 30, 2022 | -513.79% |
| Jun 30, 2022 | -557.16% |
| Dec 31, 2021 | 2,011,779.58% |
| Mar 31, 2021 | -15,501.82% |
| Dec 31, 2020 | 10,438.67% |
| Sep 30, 2020 | -5,923.96% |
| Jun 30, 2019 | -4,016.46% |
| Jun 30, 2018 | -3,985.69% |
| Mar 31, 2018 | -14,220.83% |
| Dec 31, 2017 | -8,404.61% |
| Sep 30, 2017 | -7,895.38% |
| Jun 30, 2017 | -9,174.81% |
| Mar 31, 2017 | -142,938.56% |
| Sep 30, 2015 | -3,599.56% |
| Jun 30, 2015 | -4,547.78% |
| Mar 31, 2015 | -6,018.14% |